ReviewCureus2024

Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.

Bikash R Meher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.